Loading
A phase 1/2 trial of Pembrolizumab, Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Tvardi Therapeutics, Incorporated, now recruiting.
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT05440708 by Tvardi Therapeutics, Incorporated, with 193 participants planned, started 2023-03-23 and due to reach its primary completion in 2027-02-01. Interventions recorded: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/